Last reviewed · How we verify
ACB
ACB is an anticoagulant that works by inhibiting Factor Xa.
ACB is an anticoagulant that works by inhibiting Factor Xa. Used for Non-valvular atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | ACB |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACB specifically binds to and inhibits Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. This mechanism of action is similar to other Factor Xa inhibitors, such as rivaroxaban and apixaban. By inhibiting Factor Xa, ACB reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Approved indications
- Non-valvular atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism
Common side effects
- Major bleeding
- Gastrointestinal bleeding
- Hemorrhage
Key clinical trials
- Effect of Acute Hypoxia on RIght VEntRicular Function in Healthy Adults. (NA)
- A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years (PHASE1)
- Postoperative Analgesic Benefit of iPACK Block in the Anterior Cruciate Ligament Reconstruction Surgery (NA)
- SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty (NA)
- VENTILATION DURING SPACEFLIGHT (PHASE 2) (NA)
- Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO (PHASE4)
- Effect of Acute Hypoxia on RIght VEntRicular Function in Asthma. (NA)
- Effect of Acute Hypoxia on RIght VEntRicular Function in HAPE. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACB CI brief — competitive landscape report
- ACB updates RSS · CI watch RSS
- NYU Langone Health portfolio CI